

# Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia

**Status:** Recruiting

## Eligibility Criteria

**Age:** 1 year to 17 years old

This study is NOT accepting healthy

**Healthy Volunteers:** volunteers

### Inclusion Criteria:

- Diagnosis of lymphoma or acute lymphoblastic leukemia
- Candidate for a minimum of 2 cycles HDMTX (5 g/m<sup>2</sup>) in the inpatient setting
- Creatinine clearance  $\geq$  65 mL/min by modified Schwartz equation
- Patients of childbearing potential must have a negative pregnancy test (serum or urine)
- Lactating female patients must agree not to nurse a child while on this trial
- All patients and/or their parents or legal guardians must provide written informed consent, with assent provided if applicable

---

### Exclusion Criteria:

- Trisomy 21
- History of dialysis within 30 days prior to study registration or currently on dialysis
- Polyuric renal dysfunction
- Pregnancy
- Known or suspected pleural effusion
- Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

## Conditions & Interventions

### Interventions:

Drug: Intravenous fluids

### Conditions:

Lymphoma, Acute Lymphoblastic Leukemia, Pediatric Cancer, Pediatric ALL, Pediatric Lymphoma

### Keywords:

High Dose Methotrexate, HDMTX, Intravenous Fluids

## More Information

**Contact(s):** Cady P Noda, Pharm.D. - cady.noda@vcuhealth.org

**Principal Investigator:** Noda, Cady, Ploessl

**Phase:** Phase 1

### IRB

**Number:** HM20016430

**System ID:** NCT03964259

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cctr.vcu.edu> to find a Study which is right for you and contact [ctrrecruit@vcu.edu](mailto:ctrrecruit@vcu.edu) if you have questions or need assistance.